Teva Pharma (TEVA) Reports In-Line Q1 EPS; Narrows Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Teva Reports First Quarter 2022 Financial Results
May 3, 2022 7:00 AM EDTRevenues of $3.7 billion GAAP diluted loss per share of $0.86 Non-GAAP diluted EPS of $0.55 Cash flow used in operating activities of $49 million Free cash flow of $117 million 2022 revenue outlook revised lower to reflect ongoing impact of foreign exchange fluctuations; COPAXONE® outlook revised lower mainly to reflect increased competition and foreign exchange fluctuations; all other key components reaffirmed: Revenues of $15.4 - $16.0 billion vs. previous range of $15.6 - $16.2 billion COPAXONE revenues of approximately $750 million vs. previous outlook of approximately $850 million Adjusted EBITDA of $4.7 - $5.0... More
